Brian W Dymock
Overview
Explore the profile of Brian W Dymock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
601
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sartain F, Viecelli A, Veitch M, Franklin M, Dymock B, Wells J, et al.
Transpl Int
. 2024 Feb;
37:12019.
PMID: 38323070
Solid organ transplant recipients are at an increased risk of developing skin cancers due to chronic immunosuppression, particularly with calcineurin inhibitors. Tacrolimus is the most prescribed calcineurin inhibitor in this...
2.
Veitch M, Beaumont K, Pouwer R, Chew H, Frazer I, Soyer H, et al.
J Immunother Cancer
. 2023 Sep;
11(9).
PMID: 37678918
Background: Immunosuppressive drugs such as tacrolimus have revolutionized our ability to transplant organs between individuals. Tacrolimus acts systemically to suppress the activity of T-cells within and around transplanted organs. However,...
3.
Soumyanarayanan U, Ramanujulu P, Mustafa N, Haider S, Nee A, Tong J, et al.
Eur J Med Chem
. 2019 Oct;
184:111755.
PMID: 31627059
Herein, we report the discovery of a dual histone deacetylase inhibitor displaying a unique HDAC3/6 selectivity profile. An initial strategy to merge two epigenetic pharmacophores resulted in the discovery of...
4.
See C, Kitagawa M, Liao P, Lee K, Wong J, Lee S, et al.
Bioorg Med Chem Lett
. 2018 Dec;
29(2):216-219.
PMID: 30503634
A131 (1) possesses a unique cancer cell selective dual mechanism of action where cancer cells are killed but normal cells only undergo growth arrest and are able to regrow after...
5.
Chu-Farseeva Y, Mustafa N, Poulsen A, Tan E, Yen J, Chng W, et al.
Eur J Med Chem
. 2018 Sep;
158:593-619.
PMID: 30243158
Specifically blocking more than one oncogenic pathway simultaneously in a cancer cell with a combination of different drugs is the mainstay of the majority of cancer treatments. Being able to...
6.
See C, Kitagawa M, Liao P, Lee K, Wong J, Lee S, et al.
Eur J Med Chem
. 2018 Jul;
156:344-367.
PMID: 30015072
Selective targeting of cancer cells over normal cells is a key objective of targeted therapy. However few approaches achieve true mechanistic selectivity resulting in debilitating side effects and dose limitation....
7.
Seah K, Loh J, Nguyen T, Tan H, Hutchinson P, Lim K, et al.
Exp Cell Res
. 2018 Jul;
370(2):283-291.
PMID: 29959912
Chemotherapy remains the most prescribed anti-cancer therapy, despite patients suffering severe side effects and frequently developing chemoresistance. These complications can be partially overcome by combining different chemotherapeutic agents that target...
8.
Yao L, Ramanujulu P, Poulsen A, Ohlson S, Dymock B
Bioorg Med Chem Lett
. 2018 Jun;
28(15):2636-2640.
PMID: 29945795
Inhibition of more than one pathway in a cancer cell with a single molecule could result in better therapies with less complex dosing regimens. In this work multi-component ligands have...
9.
Yao L, Ohlson S, Dymock B
Bioorg Med Chem Lett
. 2018 Mar;
28(8):1357-1362.
PMID: 29545103
Inhibition of multiple signaling pathways in a cancer cell with a single molecule could result in better therapies that are simpler to administer. Efficacy may be achieved with reduced potency...
10.
Kitagawa M, Liao P, Lee K, Wong J, Shang S, Minami N, et al.
Nat Commun
. 2017 Dec;
8(1):2200.
PMID: 29259156
Achieving robust cancer-specific lethality is the ultimate clinical goal. Here, we identify a compound with dual-inhibitory properties, named a131, that selectively kills cancer cells, while protecting normal cells. Through an...